Medtronic – Intrepid™ Early Feasibility Study Intermediate-Term Outcomes
Dr. Firas Zahr, MD, interventional cardiologist and co-director of the Complex Heart Valve Program at Oregon Health & Science University (OHSU) and Director of Interventional Cardiology at OHSU discusses findings from the Intrepid™ Early Feasibility Study Intermediate-Term Outcomes which were presented as part of the Mitral Innovation Session, at the 34th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. Results demonstrated successful device implantation and valve performance and include higher rates of successful device implantation (96.7%) and near complete elimination of mitral regurgitation (MR) in all patients (91%). Visit the Apollo Intrepid Transcatheter Mitral Valve Regurgitation Clinical Trial at Medtronic.com under the Healthcare Professionals Tab.
Dr. Firas Zahr, MD is a Internal Medicine Specialist in Portland, OR and has over 17 years of experience in the medical field. He graduated from C.U. Shah Medical College in 2005. He is affiliated with OHSU Hospital – Marquam Hill Campus.
